KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Shares Outstanding (Diluted Average) (2017 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Shares Outstanding (Diluted Average) for 13 consecutive years, with $56.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 0.88% to $56.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.5 million through Dec 2025, up 0.88% year-over-year, with the annual reading at $56.5 million for FY2025, 0.88% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $56.5 million at Supernus Pharmaceuticals, up from $56.1 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $62.5 million in Q1 2023, with the low at $54.2 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $57.2 million, with a median of $56.0 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) grew 13.47% in 2022, then fell 11.27% in 2023.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $54.4 million in 2021, then increased by 13.47% to $61.7 million in 2022, then fell by 10.01% to $55.5 million in 2023, then grew by 0.81% to $56.0 million in 2024, then grew by 0.88% to $56.5 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $56.5 million, $56.1 million, and $56.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.